By Dean Seal
Danaher reported higher earnings and revenue in the fourth quarter from gains in its life-sciences and biotechnology units, though it expects the top line to decline in the first quarter.
The manufacturing conglomerate posted a profit of $1.09 billion, or $1.49 a share, compared with $1.08 billion, or $1.45 a share, in the same quarter a year ago.
Stripping out one-time items, adjusted earnings were $2.14. Analysts surveyed by FactSet had been expecting $2.16 a share.
Sales rose 2% to $6.54 billion, above analyst projections for $6.44 billion, according to FactSet.
Revenue was up 6.3% in its biotechnology segment and 5.3% in its life-sciences division, offsetting a decline in the diagnostics business, its largest top line contributor.
Core revenue, which adjusts for foreign currency translation, acquisitions and divested product lines, was up 1%.
For the quarter ahead, Danaher expects core revenue to decline in the low-single-digit percentage range, but rise about 3% for the full year.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 29, 2025 06:29 ET (11:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.